Browse diseases

…cal malignancies, its application in solid tumors, particularly GIM, remains in its nascent stages. This comprehensive landscape an…

…DPN-CAR T cell and GD2-CAR T cell blend to target heterogeneous GBM.Methods Target antigen screening included clinical samples, cel…

…unotherapy for patients with refractory or relapsed lymphoma or leukemia. However, inefficient activity and insufficient persistence of …

…rior stability and potent antitumor activity. In vivo models of gastric cancer and breast cancer, XL-11, by reducing TIL-Tregs and increasing …

…ating hematological malignancies; however, their application to solid tumors remains challenging due to the hostile tumor microenvironment (…

…d as alternative approaches, showing early signs of activity in solid tumors. Despite these advances, single-lineage ex vivo CAR approaches …

…y for hematological malignancies but faces critical barriers in solid tumors due to tumor antigen heterogeneity and on-target, off-tumor tox…

…rapies have transformed the treatment options for patients with hematological malignancies, yet more than 50% of patients do not derive a durable benefit.…

…ll receptors (TCR-Ts), have led to promising new treatments for hematological malignancies. However, due to the complex multi-step manufacturing process, …

…round CAR-T therapy has demonstrated curative potential against hematological malignancies, but its success in solid tumors is limited by factors such as …

…ns These collective data support the development of AB-3028 for mCRPC.…

…significant momentum in recent years, particularly for treating hematological malignancies. To enhance the functional aspects of NK cells and to achieve s…